Clinical Trials Browser

Phase 3 × Completed × Gefitinib × Clear all

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

NCT01774721 2023-11-14

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

Phase 3 Completed

452 enrolled 35 charts 1 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT01404260 2017-01-27

ISCAN

Phase 3 Completed

219 enrolled 7 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01017874 2015-07-08

A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer

Phase 3 Completed

236 enrolled 15 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00049543 2015-01-01

Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery

Phase 3 Completed

503 enrolled 12 charts

Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung

NCT00034879 2013-01-04

Iressa Expanded Access Program (EAP)

Phase 3 Completed

Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

NCT00478049 2012-06-06

ISTANA

Phase 3 Completed

163 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00076388 2011-05-13

Iressa Versus Docetaxel (Taxotere)

Phase 3 Completed

1,440 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00206219 2011-01-27

Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX)

Phase 3 Completed

477 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT00455936 2010-10-25

First-line Gefitinib Versus Chemotherapy for Lung Adenocarcinoma in Never Smoker

Phase 3 Completed

315 enrolled

Thoracic

Adenocarcinoma, Lung Neoplasms

NCT00635973 2009-04-22

Open-Label Extension of Other SZ1839 (Iressa) Trials

Phase 3 Completed

100 enrolled

Tumor-Agnostic

Neoplasms

NCT00080340 2008-01-15

Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Phase 3 Completed

520 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00252707 2007-12-18

Iressa 2nd Line Phase III Study in Japan

Phase 3 Completed

484 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

FLAURA

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

ISCAN

A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer

Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery

Iressa Expanded Access Program (EAP)

ISTANA

Iressa Versus Docetaxel (Taxotere)

Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX)

First-line Gefitinib Versus Chemotherapy for Lung Adenocarcinoma in Never Smoker

Open-Label Extension of Other SZ1839 (Iressa) Trials

Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Iressa 2nd Line Phase III Study in Japan